Skip to main content

Table 2 Percent changes in cerebrospinal fluid and plasma amyloid-β 1–40 levels from baseline at day 28 across treatment groups

From: Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Safety analysis set Caucasian Japanese
Early AD Preclinical AD
Percent change from baseline at day 28 Placebo JNJ-54861911 Placebo JNJ-54861911
10 mg 50 mg 10 mg 50 mg
CSF Aβ1–40 (ng/L), n 13 14 15 6 6 6
 Mean (SD) 3.33 (12.389) − 67.30 (10.602) − 89.93 (3.535) − 7.36 (12.122) − 68.21 (16.174) − 87.15 (3.898)
 Median (range) − 0.30 (− 10.3; 32.9) − 65.22 (− 89.7; − 53.6) − 90.66 (− 97.8; − 85.9) − 9.18 (− 21.7; 9.0) − 61.36 (− 99.9; − 57.7) − 86.91 (− 92.2; − 81.5)
 95% CI of mean (− 4.16; 10.82) (− 73.42; − 61.18) (− 91.89; − 87.97) (− 20.08; 5.36) (− 85.18; − 51.23) (− 91.24; − 83.06)
 LS mean 2.73 − 66.65 − 90.01 − 6.48 − 68.96 − 87.29
 Difference of LS means (SE) − 69.37 (3.890) − 92.74 (3.630) − 62.48 (7.386) − 80.81 (7.145)
 95% CI (− 72.25; − 61.50) (− 100.08; − 85.39) (− 78.32; − 46.64) (− 96.13; − 65.49)
Plasma Aβ1–40 (ng/L) (4 hours postdose), n 14 15 16 6 6 6
 Mean (SD) − 9.36 (27.288) − 83.78 (6.022) − 92.89 (3.117) − 11.79 (8.047) − 82.73 (3.508) − 91.49 (4.403)
 Median (range) − 2.37 (− 87.3; 29.2) − 84.83 (− 95.3; − 72.4) − 94.13 (− 95.6; − 86.3) − 8.98 (− 23.0; −3.2) − 82.48 (− 88.8; − 78.7) − 91.01 (− 96.3; − 84.3)
 95% CI of mean (− 25.12; 6.39) (− 87.11; − 80.44) (− 94.55; − 91.23) (− 20.24; − 3.35) (− 86.41; − 79.05) (− 96.11; − 86.87)
 LS mean − 9.65 − 83.45 − 92.95 − 11.79 − 82.73 − 91.49
 Difference of LS means (SE)   − 73.80 (6.058) − 83.30 (5.820) − 70.94 (3.394) − 79.70 (3.390)
 95% CI   (− 86.04; − 61.57) (− 95.06; − 71.55) (− 78.22; − 63.66) (− 86.97; − 72.43)
  1. Abbreviations: AD Alzheimer’s disease, Amyloid-beta, CSF Cerebrospinal fluid, LS Least squares